The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care

British Journal of Haematology - Tập 129 Số 1 - Trang 3-17 - 2005
Corey Casper1
1Department of Medicine, Division of Infectious Disease, University of Washington School of Medicine, and The Program in Infectious Disease, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Tóm tắt

SummaryFifty years ago, Dr Benjamin Castleman first described the unusual lymphoproliferative disorder that now bears his name. Over the subsequent decades, astute clinical and pathologic observations coupled with clever molecular biologic research have increased our understanding of the aetiology of Castleman disease (CD). This article proposes three broad CD variants based on both distinctive histopathology and clinical behaviour. The pivotal roles of infection with human herpesvirus 8 and interleukin‐6 production in the development of CD are emphasized. Finally, the natural history of CD and the myriad of therapeutic options are reviewed in the context of a unified model of CD pathophysiology, and continued areas of uncertainty are discussed.

Từ khóa


Tài liệu tham khảo

10.1086/342696

10.1023/A:1008325114144

10.1182/blood.V93.12.4034

10.1089/152581600319351

10.1182/blood.V97.8.2526

10.1056/NEJM199403033300904

10.1182/blood.V93.11.3643

10.1086/515169

10.1177/39.3.1704393

10.1182/blood-2004-01-0158

Bertero M.T., 2000, Cyclophosphamide/cyclosporin‐A treatment of multicentric Castleman's disease with Kaposi's sarcoma, Haematologica, 85, 216

10.1002/jmv.10217

10.1080/17843286.2000.11754278

10.1002/(SICI)1097-0142(19990201)85:3<706::AID-CNCR21>3.0.CO;2-7

10.1172/JCI114749

Cangiarella J., 1997, Potential pitfalls in the diagnosis of Castleman's disease of the mediastinum on fine needle aspiration biopsy, Acta Cytologica, 41, 951

10.1086/314956

10.1182/blood-2003-05-1721

10.1056/NEJM195401072500107

10.1002/1097-0142(195607/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4

10.1126/science.7997879

10.1002/1097-0142(20010801)92:3<670::AID-CNCR1369>3.0.CO;2-Q

10.1097/00000478-200205000-00013

10.1093/clinids/22.6.1120

10.1182/blood.V98.12.3473

10.1182/blood-2002-07-2299

10.1182/blood.V95.4.1406.004k26_1406_1412

Flendrig J.A., 1969, Benign giant lymphoma: the clinical signs and symptoms and the morphological aspects, Folia Medica, 12, 119

10.1038/nm0195-27

10.1002/(SICI)1096-9896(199709)183:1<44::AID-PATH1103>3.0.CO;2-I

10.1016/S0140-6736(04)16308-3

Frizzera G., 1988, Castleman's disease and related disorders, Seminars in Diagnostic Pathology, 5, 346

10.1200/JCO.1985.3.9.1202

10.1093/ajcp/69.1.86

10.1007/s00277-003-0718-x

10.1086/593567

10.1172/JCI200417803

10.1111/j.1365-2559.1989.tb02162.x

Hanson C.A., 1988, Clonal rearrangement for immunoglobulin and T‐cell receptor genes in systemic Castleman's disease. Association with Epstein–Barr virus, American Journal of Pathology, 131, 84

10.7326/0003-4819-128-8-199804150-00010

10.1046/j.1365-2141.2003.04358.x

10.1002/ajh.10467

Kane K.F., 1996, Antiproliferative responses to two human colon cancer cell lines to vitamin D3 are differently modified by 9‐cis‐retinoic acid, Cancer Research, 56, 623

10.1006/viro.2000.0196

Katano H., 2001, Expression of human herpesvirus 8 (HHV‐8)‐encoded immediate early protein, open reading frame 50, in HHV‐8‐associated diseases, Journal of Human Virology, 4, 96

10.1172/JCI119380

10.1002/1097-0142(197203)29:3<670::AID-CNCR2820290321>3.0.CO;2-#

10.1002/(SICI)1096-9071(199709)53:1<81::AID-JMV14>3.0.CO;2-#

10.1182/blood.V86.4.1243.bloodjournal8641243

10.2214/ajr.182.3.1820769

10.1097/00002030-200402200-00037

10.1086/313979

10.1002/ajh.10310

10.1111/j.1468-1293.2004.00204.x

10.1182/blood-2003-03-0951

10.1034/j.1600-0609.2003.00038.x

Martin J.M., 1985, Giant lymph node hyperplasia (Castleman's disease) of hyaline vascular type. Clinical heterogeneity with immunohistologic uniformity, American Journal of Clinical Pathology, 84, 439, 10.1093/ajcp/84.4.439

10.1097/00002030-199711000-00006

10.1097/00007611-200194050-00004

10.1093/ajcp/105.3.268

Menke D.M., 2000, Ly‐1b cells and Castleman disease, Blood, 96, 1614, 10.1182/blood.V96.4.1614

10.1309/7243-AV50-KJ28-V6J9

Moore D.F., 1996, Prognostic implications following an indeterminate diagnostic work‐up of lymphoma, Blood, 88, 229a

10.1126/science.274.5293.1739

Murray P.G., 1995, Localization of Epstein–Barr virus in Castleman's disease by in situ hybridization and immunohistochemistry, Hematologic Pathology, 9, 17

10.1212/WNL.34.6.712

10.1080/10428190410001693533

10.1128/AAC.41.12.2754

10.1046/j.1365-2141.1999.01208.x

10.1182/blood.V95.1.56.001k13_56_61

10.1258/095646203321043309

10.1093/ajcp/101.3.290

10.2169/internalmedicine.42.735

10.1097/00002030-199601000-00009

10.1182/blood.V96.6.2069.h8002069_2069_2073

10.1182/blood.V99.7.2331

10.1007/s004310051166

Parravinci C., 1997, Expression of a virus‐derived cytokine, KSHV vIL‐6, in HIV‐seronegative Castleman's disease, American Journal of Pathology, 151, 1517

Peterson B.A., 1993, Multicentric Castleman's disease, Seminars in Oncology, 20, 636

10.1097/00003072-200304000-00015

10.1086/517111

10.1016/S0140-6736(99)03957-4

10.3109/15513819009067149

Sato K., 1993, Reshaping a human antibody to inhibit the interleukin 6‐dependent tumor cell growth, Cancer Research, 53, 851

10.1002/jmv.10500

10.1016/0002-9343(94)90350-6

10.1182/blood.V86.4.1276.bloodjournal8641276

10.1182/blood.V86.3.1131.1131

10.1259/0007-1285-64-758-165

10.1046/j.1440-1827.2001.01266.x

10.1136/jcp.36.9.1005

10.1016/S0046-8177(85)80065-4

10.1046/j.1365-2141.2003.04120.x

10.1182/blood.V74.4.1360.1360

Zancai P., 2004, Retinoic acid inhibits IL‐6‐dependent but not constitutive STAT3 activation in Epstein–Barr virus‐immortalized B lymphocytes, International Journal of Oncology, 25, 345

10.1056/NEJM199906173402415

Zoeteweij J.P., 1999, Identification and rapid quantification of early‐ and late‐lytic human herpesvirus 8 infection in single cells by flow cytometric analysis: characterization of antiherpesvirus agents, Journal of Virology, 73, 5894, 10.1128/JVI.73.7.5894-5902.1999

Thông tin
Thông tin xuất bản

British Journal of Haematology

Tập 129 Số 1

3-17

Thông tin tác giả